A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

被引：94
|
作者：
Wohl, David A. [1 ]
Cohen, Calvin [2 ]
Gallant, Joel E. [3 ]
Mills, Anthony [4 ]
Sax, Paul E. [5 ]
DeJesus, Edwin [6 ]
Zolopa, Andrew [7 ]
Liu, Hui C. [8 ]
Plummer, Andrew [8 ]
White, Kirsten L. [8 ]
Cheng, Andrew K. [8 ]
Rhee, Martin S. [8 ]
Szwarcberg, Javier [8 ]
机构：
[1] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27514 USA
[2] Community Res Initiat New England, Boston, MA USA
[3] Southwest Care Ctr, Santa Fe, NM USA
[4] Anthony Mills MD Inc, Los Angeles, CA USA
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA
[6] Orlando Immunol Ctr, Orlando, FL USA
[7] Stanford Univ, Div Infect Dis & Geog Med, Palo Alto, CA 94304 USA
[8] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2014年 / 65卷 / 03期
关键词：
CO-FORMULATED ELVITEGRAVIR; DOUBLE-BLIND; DISOPROXIL FUMARATE; PHASE-3; TRIAL;
D O I：
10.1097/QAI.0000000000000057
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E118 / E121
页数：5
相关论文
共 50 条
  • [1] Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
    Clumeck, Nathan
    Molina, Jean-Michel
    Henry, Keith
    Gathe, Joseph
    Rockstroh, Juergen K.
    DeJesus, Edwin
    Wei, Xuelian
    White, Kirsten
    Fordyce, Marshall W.
    Rhee, Martin S.
    Szwarcberg, Javier
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : E121 - E124
  • [2] Single-tablet regimen with elvitegravir, cobicistat, emtricitabine and tenofovir for the treatment of early HIV infection
    Teira, Ramon
    Galindo, Maria
    Montero, Marta
    Portilla, Raquel
    Ferrer, Ana
    Martinez, Elisa
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [3] Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen
    Mathias, Anita A.
    Hinkle, John
    Menning, Mark
    Hui, James
    Kaul, Sanjeev
    Kearney, Brian P.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (02) : 167 - 173
  • [4] Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
    Arribas, Jose R.
    DeJesus, Edwin
    van Lunzen, Jan
    Zurawski, Christine
    Doroana, Manuela
    Towner, William
    Lazzarin, Adriano
    Nelson, Mark
    McColl, Damian
    Andreatta, Kristen
    Swamy, Raji
    Szwarcberg, Javier
    Thai Nguyen
    [J]. HIV CLINICAL TRIALS, 2017, 18 (03): : 118 - 125
  • [5] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Cohen, Calvin
    Elion, Richard
    Ruane, Peter
    Shamblaw, David
    DeJesus, Edwin
    Rashbaum, Bruce
    Chuck, Steven L.
    Yale, Kitty
    Liu, Hui C.
    Warren, David R.
    Ramanathan, Srinivasan
    Kearney, Brian P.
    [J]. AIDS, 2011, 25 (06) : F7 - F12
  • [6] Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
    Pozniak, Anton
    Flamm, Jason
    Antinori, Andrea
    Bloch, Mark
    Ward, Douglas
    Berenguer, Juan
    Cote, Pierre
    Andreatta, Kristen
    Garner, William
    Szwarcberg, Javier
    Nguyen-Cleary, Thai
    McColl, Damian J.
    Piontkowsky, David
    [J]. HIV CLINICAL TRIALS, 2017, 18 (04): : 141 - 148
  • [7] An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents
    Giacomet, Vania
    Cossu, Maria V.
    Capetti, Amedeo F.
    Zuccotti, GianVincenzo
    Rizzardini, Giuliano
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (03) : 269 - 276
  • [8] Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1
    Negredo, Eugenia
    Clotet, Bonaventura
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 929 - 934
  • [9] Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
    White, Kirsten L.
    Kulkarni, Rima
    McColl, Damian J.
    Rhee, Martin S.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    [J]. ANTIVIRAL THERAPY, 2015, 20 (03) : 317 - 327
  • [10] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults
    Caroline M. Perry
    [J]. Drugs, 2014, 74 : 75 - 97
12345